Cao Bao Shan

2003 7,2008 6 2002 2007.2003 9, 、,2013,2014 -2018,2015.12-2016.6 Ernest Mario,.2017.7- 2018.8,, 、;2018.8-. “ ” 、; “ 、 ”; “ ”. 5, 1 、 1 、 1 、 1 、 1, 3. 15.,;,;,,;,;,;,;,;,;,; 《 》;《 》;Acta Pharmacologica Sinica、Asia-Pacific Journal of Clinical Oncology 2018 1, (XZ2017ZR-ZYZ20) 2018 - 1,Nrf2.2018 1, - HER2 (81871363) 2013 1:. 2013, 1 (NO81272468):Nrf2/ARE /. 2012 1:Nrf2/Keap1 EGFR-TKI NSCLC 1),,,,,, *, NLR PLR,,2018,21(6): 481-492. 2),,,,, *, Nrf2、Keap1 104,,2018, 21(3):241-250 3) Que L, He L, Yu C, Yin W, Ma L, Cao B*, Yu S*.Activation of Nrf2-ARE signaling mitigates cyclophosphamide-induced myelosuppression. Toxicol Lett. 2016 Sep 12; 262:17-26 4), *,, PC9.,2015,18(2), pp 98-103 5),,,,, *, Nrf2 EGFR EGFR-TKIs.,2014,17(2), pp 155-162. 6),,,. E2 2.,2012,32(11): 919-924 7),,,. Nrf2 mRNA.,2012,32(2): 124-129 8),,,. CD13 A549.,2012,39(22):1778-1782 9),,,. Keap1. 2012,15(10):591-597 10) Cao B, Jia J, Ma L, et al. Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. Clin Transl Oncol, 2012, 14(8):575-585. 11),,,. A549 H460. 2009,17(1):8-12 12),,,. 、 B12.,2011,15(12):2085-208 13),..,2008,40 (5): 555-557 14),. CXCL12/CXCR4.. 2008,15(2):176-178 15) Li F, Zhu T, Cao B, Wang J, Liang L. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.Eur J Cancer. 2017;84:184-192. 16) Guo Z, Yi F, Yin W, Zhang Y, Li Q, Gu Y, Xiao Y, Cao B, Ma L, Liang L. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.Thorac Cancer. 2017;8(3):159-169. 17) Chen H, Cao B, Chen H, Lin YS, Zhang J. Combination of antibody-coated, physical-based microfluidic chip with wave-shaped arrays for isolating circulating tumor cells.Biomed Microdevices. 2017;19(3):66. 18) Chen H, Cao B, Sun B, Cao Y, Yang K, Lin YS. Highly-sensitive capture of circulating tumor cells using micro-ellipse filters.Sci Rep. 2017 Apr 4;7(1):610. 19) Liang L, Fan Y, Cheng J, Cheng D, Zhao Y, Cao B, Ma L, An L, Jia W, Su X, Yang J, Zhang H. TAK1 ubiquitination regulates doxrubincin-induced NF-κB activation. Cell Signal. 2013, 25(1):247-254. 20) Yao HW, Xiu DR, Fu W, Yuan J, Jiang B, Wang DC, Ma CL, Yuan CH, Sun T, Ma LW, Cao BS, Liu JY, Chen M, Chen W, Tan S, Huang YH, Zhang L, Shi XY.[A clinical study on multi-disciplinary team and surgery for resectable colorectal cancer with liver metastases]. Zhonghua Wai Ke Za Zhi. 2012,50(11):961-5. 21) Lin-Ling Que, Hui-Xia Wang, Bao-Shan Cao, Xiao-Da Yang, Kui Wang, Si-Wang Yu.The regulation and functions of transcription factor Nrf2 in cancer chemoprevention and chemoresistance Journal of Chinese Pharmaceutical Sciences 2011,1:5-19 《 》 《 》, 《 》.